Veranex

Veranex is a growth-equity-backed operating company rather than a fund, so investment decisions are corporate strategy choices led by CEO David Dockhorn and the Board of Directors. The private equity sponsor, Summit Partners, has significant influence over capital allocation and M&A strategy. Rick Anderson, appointed Board Chairman in October 2023, brings decades of medtech commercial experience to governance decisions.

Veranex is a portfolio company of Summit Partners, which created it by merging six existing service firms in 2021. It is not a single-family office or a venture firm — it is an operating company delivering professional services. Summit Partners holds a controlling interest and historically exits such investments via sale to a larger strategic buyer or another financial sponsor, though no exit timeline has been publicly articulated.

Veranex works across general surgery, orthopedics, cardiovascular devices, robotic surgery tools, digital health applications, and combination products. The firm does not publicly list which specific OEMs or brands it supports, as development agreements with regulated device makers are typically confidential. The U.S. Army Medical Materiel Development Activity is one disclosed public-sector client.

The firm's business development model relies on the existing commercial relationships its six legacy companies brought to the merger in 2021. Its regulatory and clinical expertise also functions as a lead-generation tool — device companies frequently need to solve a regulatory problem before they need a new design project, and Veranex can capture both phases of the engagement.

There is no public evidence that Veranex takes equity positions in the device companies it serves. It operates on a fee-for-service model, common among contract research and design firms. Summit Partners may make separate equity investments through its funds, but those are not conducted through the Veranex operating entity.